Monday, June 14th 2021
11:30 AM - 1:00 PM
Traditional methods of hepatitis C education, testing, linkage and subspecialty care were not conducive to providing safe and effective services during the COVID-19 pandemic. The C a Difference team at Philadelphia FIGHT quickly mobilized to ensure continuity of safe and reliable gold-standard health care to our our clients, patients and partnering providers. Many of the care protocols developed during the pandemic will be carried on even as COVID-19 restrictions are lifted to better reach those we serve.
- Safer protocols and alternatives to rapid community testing for hepatitis C will be shared
- Remote patient linkage and navigation strategies will be discussed
- The importance of implementing and supporting HCV telehealth at inpatient and outpatient community partnering sites will be presented
- Lessons learned and future goals of HCV subspecialty care will be examined
Lora Magaldi is the Viral Hepatitis Department Manager at Philadelphia FIGHT.
Stacey Trooskin, MD PhD
Stacey Trooskin, MD, PhD is Chief Medical Officer and Director of Viral Hepatitis Programs at Philadelphia FIGHT Community Health Centers and is a faculty member of the Infectious Diseases Division at the University of Pennsylvania, Perelman School of Medicine. Dr. Trooskin received her MPH in Public Health from Yale University, her PhD (Epidemiology) from Rutgers School of Public Health and her MD from the University of Medicine and Dentistry of New Jersey, at the Robert Wood Johnson School of Medicine. Dr. Trooskin specializes in infectious diseases, HIV medicine, HIV/HCV co-infection, and internal medicine. She has an interest in public health, particularly the epidemiology of hepatitis C and identifying and overcoming barriers to testing and treatment. She recently completed a 3 year term of service as a member of the AASLD/IDSA HCV treatment guidance panel and currently serves as the Chief Medical Advisor to the National Viral Hepatitis Roundtable and is a member of the Technical Advisory Board (TAB) of the Coalition for Global Hepatitis Elimination.